Olema Pharmaceuticals, Inc. (OLMA)

Market Cap	1.38B
Revenue (ttm)	n/a
Net Income (ttm)	-149.96M
Shares Out	68.66M
EPS (ttm)	-1.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,327,557
Open	26.46
Previous Close	8.52
Day's Range	18.11 - 27.17
52-Week Range	2.86 - 27.17
Beta	2.08
Analysts	Strong Buy
Price Target	28.67 (+42.35%)
Earnings Date	Nov 10, 2025

About OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a mono...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2020
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: OLMA
• Website: https://olema.com

Analyst Summary

According to 6 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price target is $28.67, which is an increase of 42.35% from the latest price.

Price Target

$28.67

(42.35% upside)

Analyst Consensus: Strong Buy